Jw Cayman Therapeutics Co Ltd

JW (Cayman) Therapeutics Co. Ltd is a clinical-stage cell therapy company engaged in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. Its cell-based immunotherapies include CAR-T treatment, which uses human immune cells to fight cancer. The company offers Carteyva, JWCAR201, and JWCAR239 for hematological malignancies, and relmacabtagene autoleucel injection (relma-cel) as a potential treatment for systemic lupus erythematosus (SLE). Its pipeline includes JWCAR129 for multiple myeloma, JWCAR201 for B-cell malignancies and autoimmune diseases, and JWATM204, JWATM214, JWATM203, JWATM213, JWTCR001, and JWCAR031 for various solid tumors. Founded in 2016, it is headquartered in Shanghai, China.